argenx SE
ARGX614.760USD
+14.250+2.37%
收盘 04/25, 16:00（美东）报价延迟15分钟
37.35B总市值
44.84市盈率 TTM
关于 argenx SE 公司
argenx SE（前身为 arGEN X BV）是一家总部位于荷兰的生物制药公司。该公司主要致力于利用其发现平台 Simple Antibody 创建和开发用于治疗严重自身免疫性疾病的差异化抗体疗法产品线，该平台利用了骆驼免疫系统的特点。该公司开发了一系列专注于癌症和自身免疫适应症的抗体疗法产品线。它包括但不限于：Empasiprubart，一种针对 C2 的补体抑制剂，可阻断经典和凝集素途径的功能，同时保持替代途径完好无损，ARGX-119 是一种 MuSK 受体拮抗剂，具有多种神经肌肉适应症的潜力。
公司简介
公司代码ARGX
公司名称argenx SE
上市日期Jul 10, 2014
成立日期2008
CEOMr. Tim van Hauwermeiren
员工数量1599
证券类型Ordinary Share
年结日Jul 10
公司地址Laarderhoogtweg 25
城市AMSTERDAM
上市交易所Euronext Brussels
国家Netherlands
邮编1101 EB
电话31763030
网址https://www.argenx.com/
公司代码ARGX
上市日期Jul 10, 2014
成立日期2008
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Karl Gubitz
Mr. Karl Gubitz
Chief Financial Officer
Chief Financial Officer
500.00
--
Mrs. Camilla Sylvest
Mrs. Camilla Sylvest
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Tim van Hauwermeiren
Mr. Tim van Hauwermeiren
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
--
--
Dr. Ana Cespedes
Dr. Ana Cespedes
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Karen Massey
Ms. Karen Massey
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Joseph Donald (Don) debethizy, Ph.D.
Dr. Joseph Donald (Don) debethizy, Ph.D.
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Mrs. Andria Wilk
Mrs. Andria Wilk
Global Head of Quality
Global Head of Quality
--
--
Mr. Arjen Lemmen
Mr. Arjen Lemmen
Vice President - Corporate Development and Strategy
Vice President - Corporate Development and Strategy
--
--
Ms. Malini Moorthy
Ms. Malini Moorthy
General Counsel
General Counsel
--
--
Mr. Peter Ulrichts
Mr. Peter Ulrichts
Chief Scientific Officer
Chief Scientific Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Karl Gubitz
Mr. Karl Gubitz
Chief Financial Officer
Chief Financial Officer
500.00
--
Mrs. Camilla Sylvest
Mrs. Camilla Sylvest
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Tim van Hauwermeiren
Mr. Tim van Hauwermeiren
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
--
--
Dr. Ana Cespedes
Dr. Ana Cespedes
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Karen Massey
Ms. Karen Massey
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Joseph Donald (Don) debethizy, Ph.D.
Dr. Joseph Donald (Don) debethizy, Ph.D.
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
收入明细
单位: USD更新时间: 4月6日 周日
单位: USD更新时间: 4月6日 周日
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
暂无数据
地区USD
名称
营收
占比
United States
1.90B
86.56%
Rest of the World
161.25M
7.36%
Japan
89.39M
4.08%
China
43.52M
1.99%
Netherlands
153.00K
0.01%
业务
地区
暂无数据
股东统计
更新时间: 4月26日 周六
更新时间: 4月26日 周六
持股股东
股东类型
持股股东
股东统计
占比
Fidelity Management & Research Company LLC
8.87%
T. Rowe Price Associates, Inc.
7.71%
Artisan Partners Limited Partnership
5.03%
Janus Henderson Investors
3.79%
Capital World Investors
2.93%
Other
71.66%
持股股东
股东统计
占比
Fidelity Management & Research Company LLC
8.87%
T. Rowe Price Associates, Inc.
7.71%
Artisan Partners Limited Partnership
5.03%
Janus Henderson Investors
3.79%
Capital World Investors
2.93%
Other
71.66%
股东类型
股东统计
占比
Investment Advisor
32.37%
Investment Advisor/Hedge Fund
17.27%
Hedge Fund
4.50%
Research Firm
1.80%
Pension Fund
0.51%
Private Equity
0.42%
Bank and Trust
0.06%
Other
43.06%
机构持股
更新时间: 1月19日 周日
更新时间: 1月19日 周日
报告期
机构数
持股数
持股占比
持股变动
2025Q1
760
34.67M
56.84%
-3.53M
2024Q4
769
34.65M
57.94%
-3.60M
2024Q3
721
35.68M
59.67%
-2.04M
2024Q2
693
34.77M
58.16%
-2.15M
2024Q1
675
34.54M
58.16%
-754.92K
2023Q4
655
33.23M
56.14%
-574.05K
2023Q3
612
32.76M
56.24%
+237.83K
2023Q2
559
31.23M
55.80%
-1.48M
2023Q1
539
31.55M
56.67%
-1.67M
2022Q4
531
31.27M
56.45%
-2.84M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Fidelity Management & Research Company LLC
5.41M
8.87%
+798.29K
+17.31%
Dec 31, 2024
T. Rowe Price Associates, Inc.
4.70M
7.71%
-292.11K
-5.85%
Dec 31, 2024
Artisan Partners Limited Partnership
3.07M
5.03%
-443.25K
-12.62%
Dec 31, 2024
Janus Henderson Investors
2.31M
3.79%
-166.85K
-6.73%
Dec 31, 2024
Capital World Investors
1.79M
2.93%
+86.69K
+5.10%
Dec 31, 2024
Avoro Capital Advisors LLC
1.24M
2.03%
--
--
Dec 31, 2024
T. Rowe Price International Ltd
813.71K
1.33%
-11.54K
-1.40%
Dec 31, 2024
RTW Investments L.P.
673.50K
1.1%
+19.07K
+2.91%
Dec 31, 2024
ClearBridge Investments, LLC
629.83K
1.03%
+40.33K
+6.84%
Dec 31, 2024
Bellevue Asset Management AG
593.18K
0.97%
-39.65K
-6.26%
Dec 31, 2024
查看更多
持股ETF
更新时间: 4月6日 周日
更新时间: 4月6日 周日
机构名称
占比
Tema Neuroscience and Mental Health ETF
4.99%
VanEck Biotech ETF
4.9%
iShares Neuroscience and Healthcare ETF
4.31%
iShares Health Innovation Active ETF
3.47%
First Trust NYSE Arca Biotechnology Index Fund
2.96%
Goldman Sachs Future Health Care Equity ETF
2.4%
iShares Biotechnology ETF
2.32%
PGIM Jennison International Opportunities ETF
2.07%
Invesco Nasdaq Biotechnology ETF
1.93%
Harbor Health Care ETF
1.93%
查看更多
Tema Neuroscience and Mental Health ETF
占比4.99%
VanEck Biotech ETF
占比4.9%
iShares Neuroscience and Healthcare ETF
占比4.31%
iShares Health Innovation Active ETF
占比3.47%
First Trust NYSE Arca Biotechnology Index Fund
占比2.96%
Goldman Sachs Future Health Care Equity ETF
占比2.4%
iShares Biotechnology ETF
占比2.32%
PGIM Jennison International Opportunities ETF
占比2.07%
Invesco Nasdaq Biotechnology ETF
占比1.93%
Harbor Health Care ETF
占比1.93%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据